Get a free sample of Uterine Fibroid Treatment Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Uterine Fibroid Treatment Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Uterine Fibroid Treatment Drugs Market Size
Uterine Fibroid Treatment Drugs Market size was valued to be USD 1.7 billion in 2022 and is projected to reach USD 4.5 billion by 2032 with a remarkable CAGR of 10%. The expansion can be credited to significant elements like the rising occurrence of uterine fibroids, the emergence of novel medications for individuals with uterine fibroids, and the heightened consciousness regarding uterine fibroids.
Uterine fibroids, also known as leiomyomas or myomas, refers to non-cancerous tumors or growth developed in the muscular wall of the uterus and are the most common type of benign tumors that affects the female reproductive system. Uterine fibroid treatment drugs are medications are provided to alleviate the symptoms of uterine fibroids or to prepare the patient for surgical interventions. These drugs facilitate in reducing the symptoms such as heavy menstrual bleeding, pain, and pressure by targeting the hormonal regulation of fibroid growth.
Why is the demand for progestin-releasing intrauterine device (IUD) & contraceptives growing?
Progestin-releasing intrauterine device (IUD) & contraceptives segment registered 65.7% share in 2022 on account of its advantages in managing the uterine fibroids.
How big is the uterine fibroid treatment drugs market?
Uterine fibroid treatment drugs industry size reached USD 1.7 billion in 2022 and will witness 10% CAGR through 2032 due to the emergence of novel medications for individuals with uterine fibroids.
Who are the key uterine fibroid treatment drugs industry players?
Pfizer Inc., Abbvie, Inc., AstraZeneca plc, Bayer AG, Myovant Sciences Gmbh, Ferring B.V., Amring Pharmaceuticals Inc., Theramex and Watson Pharma, Inc. are some of the major uterine fibroid treatment drug companies worldwide.
What factors are influencing uterine fibroid treatment drugs market in North America?
North America uterine fibroid treatment drugs industry will witness 9.4% CAGR through 2023-2032 owing to the increasing demand for non-invasive, safe, and effective treatment options in the region.